PremiumCompany AnnouncementsCabaletta Bio Advances Clinical Trials with Lonza Partnership Cabaletta Bio announces strategic priorities, anticipated milestones for 2025 Cabaletta Bio downgraded at Evercore ISI on lack of financing clarity PremiumCompany AnnouncementsCabaletta Bio Reports Q3 2024 Financial Results Cabaletta Bio announces updated clinical data on CABA-201 Cabaletta Bio’s Promising Clinical Data on CABA-201 PremiumThe FlyCabaletta Bio initiated with a Buy at UBS Cabaletta Bio Outlines Future Trials and Development Strategy Cabaletta Bio price target lowered to $15 from $25 at Evercore ISI